Caterpillar Defined Benefit Plan, Expected Future Prescription Drug Subsidy Receipt, Year One remained flat by 0.0% to $6.00M in Q4 2025 compared to the prior quarter. Over 2 years (FY 2023 to FY 2025), Defined Benefit Plan, Expected Future Prescription Drug Subsidy Receipt, Year One shows relatively stable performance with a 0.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Higher receipts reduce the net cost of retiree benefits, improving cash flow, while lower receipts may indicate changes in subsidy eligibility or plan structure.
This represents the expected cash inflows from government subsidies related to prescription drug benefits provided under...
Common for large industrial firms with legacy pension and healthcare obligations.
other_prescription_drug_subsidy_receipts_next_twelve_months| Q4 '23 | Q4 '24 | Q4 '25 | |
|---|---|---|---|
| Value | $6.00M | $6.00M | $6.00M |
| QoQ Change | — | +0.0% | +0.0% |
| YoY Change | — | +0.0% | +0.0% |